ALK and non-small cell lung carcinoma: This study shows that detection of TP53 mutations in tissue of liquid rebiopsies at the time of disease progression in previously negative patients is associated with more aggressive clinical course, shorter TKI responses and inferior OS in ALK+ NSCLC, comparable to primary TP53 mutated cases.